Search
forLearn
5 / 801 resultslearn APISCALP™
learn inca- inch
learn procapil
learn propylparaben IP
Research
5 / 54 results
research 51895 Interim Analysis of Platelet-Rich Plasma (PRP) Treatment for Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in Breast Cancer Patients: A Randomized Controlled Trial
PRP treatment may help improve hair density and thickness in breast cancer patients with therapy-induced hair loss.
research Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
research Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia
Hair regrowth treatments had modest benefits for patients with long-term hair loss after chemotherapy.
research Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil
Low dose oral minoxidil helps regrow hair in permanent chemotherapy-induced alopecia.
research Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with low-dose oral minoxidil
The document concludes that low-dose oral minoxidil successfully regrew hair in a patient with permanent hair loss after chemotherapy and stem cell transplant.
Community Join
5 / 1000+ resultscommunity Setipiprant/PGE2 feedbacks?
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community A Short Recap on PP405 and AAD 2026
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community SCUBE3/Pyr/or anything else of interest in the piplines. any updates?
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.